Securities code: 300146 securities abbreviation: By-Health Co.Ltd(300146) Announcement No.: 2022-001
Annual performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records and errors
Leading statements or material omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance: rising in the same direction
3. Performance forecast:
The current reporting period of the project is the same period of last year
(January 1, 2021 – December 31, 2021) (January 1, 2020 – December 31, 2020)
Growth attributable to listed companies over the same period last year: 5% – 25%
Net profit of shareholders: 152.42512 million yuan
Profit: about 1600463800 yuan – 1905314100 yuan
2、 Performance forecast and pre audit
This performance forecast has not been audited by certified public accountants.
3、 Explanation of performance change reasons
1. In 2021, the company fully implemented the scientific nutrition strategy and practically promoted the established business plans,
Continue to promote business innovation and key projects, and constantly build new core competitive advantages. In July, the company launched offline
Sales change and Wuxi Online Offline Communication Information Technology Co.Ltd(300959) integrated operation related changes to support the company’s healthier and sustainable development
Slightly, it will bring certain pressure and challenges to the company and relevant parties in the short term. During the reporting period, the company’s domestic offline business
Income growth is lower than expected; Domestic online business revenue has achieved rapid growth; Overseas life space
Group Pty Ltd (hereinafter referred to as “LSG”) achieved a certain increase in revenue. Based on this, the company expects to
The performance increased by a certain margin compared with the same period last year.
2. During the reporting period, the company conducted a preliminary impairment test on the goodwill formed by the acquisition of LSG, and it is estimated that 2021
There is no risk of goodwill impairment in, which shall be subject to the audit and evaluation of audit institutions and evaluation institutions.
3. The amount of non recurring profit and loss of the company in 2020 is 379.8253 million yuan, and it is expected that the non recurring profit and loss will be in 2021
The impact of profit and loss on net profit is between 200 million yuan and 22 million yuan, mainly due to public interest during the reporting period
Government subsidies received by the company, profits and losses from changes in fair value of financial assets held by the company during the reporting period, investment income, etc. 4、 Other relevant instructions
1. This performance forecast is the preliminary calculation result of the company’s financial department, and the details can be determined only after the audit and evaluation by the audit institution and evaluation institution.
2. The specific data of 2021 annual performance will be disclosed in detail in the 2021 annual report disclosed by the company on March 5, 2022. Please make careful decisions and pay attention to investment risks.
5、 Documents for future reference
1. Description of the board of directors on the annual performance forecast in 2021.
It is hereby announced.
By-Health Co.Ltd(300146) board of directors
January 4, 2002
